-
Jacobson Pharma Leads HKD 6 Million JV for Specialty Drug Distribution
•
China-based Jacobson Pharma Corporation (HKG: 2633), Ban Loong Holdings Ltd (HKG: 0030), and JBM (Healthcare) Limited (HKG: 2161) are set to establish a joint venture (JV) with a capital of HKD 6 million (USD 764,361). The companies will hold stakes of 20%, 60%, and 20% respectively. The JV aims to…
-
Hansoh Pharmaceutical’s Ameile Accepted for UK Regulatory Review
•
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that a Marketing Authorization Application (MAA) for its epidermal growth factor receptor (EGFR) inhibitor Ameile (almonertinib) has been accepted for review by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). The application seeks approval for Ameile as a first-line treatment…
-
MegaRobo Secures USD 300 Million in Series C Round Led by Goldman Sachs
•
Beijing-based MegaRobo Technologies, a company applying robotics and artificial intelligence (AI) in the life sciences field, has reportedly secured USD 300 million in a Series C financing round. The funding was led by Goldman Sachs, GGV Capital, and Asia Investment Capital, with participation from Sinovation Ventures, Pavilion Capital, Starr Capital,…
-
China Issues Monkeypox Diagnosis Guidelines Amid Global Outbreaks
•
China’s National Health Commission (NHC) has formulated and released the “Monkeypox Diagnosis and Treatment Guidelines” (2022 Edition) in response to the recent outbreaks of monkeypox in multiple non-pandemic countries since May this year. The guidelines aim to enhance early clinical identification and standardized diagnosis and treatment, ensuring thorough preparedness against…
-
Quoin Pharmaceuticals Partners with WinHealth for Rare Disease Treatments in Greater China
•
US-based rare disease specialist Quoin Pharmaceuticals Ltd (NASDAQ: QNRX) announced a licensing and distribution agreement with Hong Kong WinHealth Pharma Group Ltd. The deal grants WinHealth rights to Quoin’s pipeline candidates QRX003 and QRX004 for Netherton syndrome and epidermolysis bullosa (EB) in the Greater China territory, including Hong Kong, Macau,…
-
US Bipartisan Bill Seeks to Regulate Investments in Chinese High-Tech Firms
•
US senators are preparing a bipartisan bill that would require US investors targeting Chinese high-tech companies, including those in the pharmaceutical sector, to seek government approval in the future. The draft proposals are part of an economic competitiveness bill aimed at countering China’s rise. Proposed MechanismThe proposals would establish a…
-
Alphamab Oncology Doses First Patient in Phase I Trial for PD-L1/OX40 Bispecific Antibody KN052
•
China-based Alphamab Oncology (HKG: 9966) has announced the dosing of the first patient in a Phase I clinical trial in China (KN052-CHN-001) for its pipeline candidate KN052. This bispecific antibody (BsAb) targets programmed-death ligand 1 (PD-L1) and OX40 and is being evaluated as a treatment for general advanced solid tumors.…
-
Walvax Biotechnology Halts EV71 Vaccine Development Amid Changing Disease Trends
•
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the decision to terminate a clinical study and end development for its recombinant enterovirus 71 (EV71) virus vaccine (Pichia pastoris). The company’s press release states that the recombinant EV71 vaccine, which first entered clinical trials in China in June 2019, was…
